KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Net Cash Flow for 4 consecutive years, with -$105.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Net Cash Flow fell 557.67% year-over-year to -$105.1 million, compared with a TTM value of -$379.4 million through Dec 2023, down 69.19%, and an annual FY2025 reading of -$393.6 million, down 2.61% over the prior year.
  • Net Cash Flow was -$105.1 million for Q4 2023 at Ginkgo Bioworks Holdings, down from -$77.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.5 billion in Q3 2021 and bottomed at -$172.4 million in Q4 2021.
  • Average Net Cash Flow over 4 years is $39.6 million, with a median of -$77.2 million recorded in 2023.
  • The sharpest move saw Net Cash Flow surged 113.33% in 2022, then tumbled 557.67% in 2023.
  • Year by year, Net Cash Flow stood at -$88.4 million in 2020, then crashed by 95.07% to -$172.4 million in 2021, then soared by 113.33% to $23.0 million in 2022, then crashed by 557.67% to -$105.1 million in 2023.
  • Business Quant data shows Net Cash Flow for DNA at -$105.1 million in Q4 2023, -$77.2 million in Q3 2023, and -$86.1 million in Q2 2023.